|

ZG006 Clinical Trials

6 actively recruiting trials across 1 location

Pipeline

Phase 1: 1Phase 3: 1Phase 1/2: 4

Top Sponsors

  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd6

Indications

  • Lung Cancer6
  • Cancer6
  • Small Cell Lung Cancer5
  • Neuroendocrine Carcinoma3
  • Neuroendocrine Cancer1

Other5 trials

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Phase 1/2
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Phase 1/2
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Phase 3
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1/2
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1/2

Orange, California1 trial

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

Zelgen Site 105

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.